These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 11290863)

  • 1. Ras biochemistry and farnesyl transferase inhibitors: a literature survey.
    Crul M; de Klerk GJ; Beijnen JH; Schellens JH
    Anticancer Drugs; 2001 Mar; 12(3):163-84. PubMed ID: 11290863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Farnesyl transferase inhibitors: a major breakthrough in anticancer therapy? Naples, 12 April 2002.
    Caponigro F
    Anticancer Drugs; 2002 Sep; 13(8):891-7. PubMed ID: 12394276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Farnesyl transferase inhibitors: one target may be found in another].
    Mazières J; Pradines A; Favre G
    Med Sci (Paris); 2003 Feb; 19(2):211-6. PubMed ID: 12836615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
    Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
    Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isotype-specific Ras.GTP-levels predict the efficacy of farnesyl transferase inhibitors against human astrocytomas regardless of Ras mutational status.
    Feldkamp MM; Lau N; Roncari L; Guha A
    Cancer Res; 2001 Jun; 61(11):4425-31. PubMed ID: 11389071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
    Sebti SM; Hamilton AD
    Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RAS and leukemia: from basic mechanisms to gene-directed therapy.
    Beaupre DM; Kurzrock R
    J Clin Oncol; 1999 Mar; 17(3):1071-9. PubMed ID: 10071302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Development of farsenyl transferase inhibitors as anticancer agents].
    Cestac P; Doisneau-Sixou S; Favre G
    Ann Pharm Fr; 2005 Jan; 63(1):76-84. PubMed ID: 15803104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytoreductive effects of farnesyl transferase inhibitors on multiple myeloma tumor cells.
    Shi Y; Gera J; Hsu JH; Van Ness B; Lichtenstein A
    Mol Cancer Ther; 2003 Jun; 2(6):563-72. PubMed ID: 12813136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Farnesyltransferase inhibitors define a role for RhoB in controlling neoplastic pathophysiology.
    Prendergast GC
    Histol Histopathol; 2001 Jan; 16(1):269-75. PubMed ID: 11193202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of SCH 59228, an orally bioavailable farnesyl protein transferase inhibitor, on the growth of oncogene-transformed fibroblasts and a human colon carcinoma xenograft in nude mice.
    Liu M; Bryant MS; Chen J; Lee S; Yaremko B; Li Z; Dell J; Lipari P; Malkowski M; Prioli N; Rossman RR; Korfmacher WA; Nomeir AA; Lin CC; Mallams AK; Doll RJ; Catino JJ; Girijavallabhan VM; Kirschmeier P; Bishop WR
    Cancer Chemother Pharmacol; 1999; 43(1):50-8. PubMed ID: 9923541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-Ras targets of farnesyltransferase inhibitors: focus on Rho.
    Lebowitz PF; Prendergast GC
    Oncogene; 1998 Sep; 17(11 Reviews):1439-45. PubMed ID: 9779989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action.
    Jabbour E; Kantarjian H; Cortes J
    Leuk Lymphoma; 2004 Nov; 45(11):2187-95. PubMed ID: 15512806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Farnesyltransferase inhibitors and anti-Ras therapy.
    Gibbs JB; Kohl NE; Koblan KS; Omer CA; Sepp-Lorenzino L; Rosen N; Anthony NJ; Conner MW; deSolms SJ; Williams TM; Graham SL; Hartman GD; Oliff A
    Breast Cancer Res Treat; 1996; 38(1):75-83. PubMed ID: 8825125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Farnesyl transferase inhibitors as anticancer agents.
    Haluska P; Dy GK; Adjei AA
    Eur J Cancer; 2002 Sep; 38(13):1685-700. PubMed ID: 12175684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perspectives on farnesyl transferase inhibitors in cancer therapy.
    Mazieres J; Pradines A; Favre G
    Cancer Lett; 2004 Apr; 206(2):159-67. PubMed ID: 15013521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Farnesyl transferase inhibitors: the next targeted therapies for breast cancer?
    O'Regan RM; Khuri FR
    Endocr Relat Cancer; 2004 Jun; 11(2):191-205. PubMed ID: 15163298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Farnesylated proteins as anticancer drug targets: from laboratory to the clinic.
    Russo P; Loprevite M; Cesario A; Ardizzoni A
    Curr Med Chem Anticancer Agents; 2004 Mar; 4(2):123-38. PubMed ID: 15032718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects.
    Feldkamp MM; Lau N; Guha A
    Oncogene; 1999 Dec; 18(52):7514-26. PubMed ID: 10602510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ras as a target in cancer therapy.
    Midgley RS; Kerr DJ
    Crit Rev Oncol Hematol; 2002 Nov; 44(2):109-20. PubMed ID: 12413630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.